SANUWAVE Health to Hold Investor Live Webcast on Wednesday, June 10, 2020
Suwanee, Ga. - 
(NewMediaWire) - June 9, 2020 - SANUWAVE Health, Inc. (OTCQB:
SNWV) announced today that the
Company will host a live webcast and conference call on Wednesday, June 10,
2020, beginning at 9AM Eastern Time to provide a business update.
Shareholders and other interested
parties can participate in the live webcast at https://www.webcaster4.com/Webcast/Page/2249/35268.
Shareholders and other interested parties can
also participate in the conference call by dialing 844-602-0380 (U.S.) or
862-298-0970 (international). Please join the call at least 10 minutes
before the start time.
A replay of the webcast and conference call
will be available beginning two hours after its completion through June 17,
2020, by dialing 877-481-4010 (U.S.) or 919-882-2331 and entering replay
passcode 35268 and a replay of the webcast will be available at https://www.webcaster4.com/Webcast/Page/2249/35268
until September 10, 2020.
About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB:SNWV) (www.SANUWAVE.com)
is a shockwave technology company initially focused on the development and commercialization
of patented noninvasive, biological response activating devices for the repair
and regeneration of skin, musculoskeletal tissue and vascular structures.
SANUWAVE’s portfolio of regenerative medicine products and product candidates
activate biologic signaling and angiogenic responses, producing new
vascularization and microcirculatory improvement, which helps restore the
body’s normal healing processes and regeneration. SANUWAVE applies its patented
PACE® technology in wound healing, orthopedic/spine, plastic/cosmetic and
cardiac conditions. Its lead product candidate for the global wound care
market, dermaPACE®, is US FDA cleared for the treatment of Diabetic Foot
Ulcers. The device is also CE Marked throughout Europe and has device license
approval for the treatment of the skin and subcutaneous soft tissue in Canada,
South Korea, Australia and New Zealand. SANUWAVE researches, designs,
manufactures, markets and services its products worldwide, and believes it has
demonstrated that its technology is safe and effective in stimulating healing
in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral
epicondylitis) through its U.S. Class III PMA approved OssaTron® device,
as well as stimulating bone and chronic tendonitis regeneration in the
musculoskeletal environment through the utilization of its OssaTron,
Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In
addition, there are license/partnership opportunities for SANUWAVE’s shockwave
technology for non-medical uses, including energy, water, food and industrial
markets.
Forward-Looking
Statements
This press
release may contain “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, such as statements relating
to financial results and plans for future business development activities, and
are thus prospective. Forward-looking statements include all statements that
are not statements of historical fact regarding intent, belief or current
expectations of the Company, its directors or its officers. Investors are
cautioned that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, many of which are beyond the
Company’s ability to control. Actual results may differ materially from those
projected in the forward-looking statements. Among the key risks, assumptions
and factors that may affect operating results, performance and financial
condition are risks associated with the regulatory approval and marketing of
the Company’s product candidates and products, unproven pre-clinical and
clinical development activities, regulatory oversight, the Company’s ability to
manage its capital resource issues, competition, and the other factors
discussed in detail in the Company’s periodic filings with the Securities and
Exchange Commission. The Company undertakes no obligation to update any
forward-looking statement.
For additional information
about the Company, visit www.sanuwave.com.
Contact:
Millennium
Park Capital LLC
Christopher Wynne
312-724-7845
cwynne@mparkcm.com
SANUWAVE
Health, Inc.
Kevin Richardson II
Chairman of the Board
978-922-2447
investorrelations@sanuwave.com
